sixmilliondollarman
Posted - 23 hours ago
$GLTO convenient injectable will pair well with oral GB1211
https://www.reuters.com/business/healthcare-pharmaceuticals/merck-says-keytruda-injection-par-with-approved-iv-version-trial-2024-11-19/
sixmilliondollarman
Posted - 2 days ago
$GLTO company is setting up to be acquired. Cleaned up capital structure without doing any financing. Not funding current trials. Only funding remaining pre IND studies for new asset. Operating with a skeleton crew. Lease expires this month and opted for short term lease exception (one year or less) going forward. Acquisition likely waiting on additional data from the ongoing oncology trials. Next month MASH data from GALT could ignite this. Bag holding now but winning soon đź‘Ť
arribaStocktrading
Posted - 2 days ago
$GLTO The pre-split price of this stock is now less than 24 cents/share.
arribaStocktrading
Posted - 2 days ago
$GLTO This "company" now spends more money paying executives that do nothing than they spend on funding R&D and clinical operations. They wasted an entire year trying to find strategic alternatives. If you take the time to read the 10K, they plainly state therein that they have absolutely no way of funding the development of the 2 drugs they either own or have rights to. But the cash burn continues and mostly, it's just money taken from the shareholders to pay executives that do nothing. That's why very few are rushing out to buy the stock even now.
PenkeTrading
Posted - 2 days ago
I found you an Oversold RSI (Relative Strength Index) on the daily chart of Galecto Inc. Is that bullish or bearish? $GLTO #RsiOversold #NASDAQ
Investor1337
Posted - 3 days ago
$GLTO news soon 🤫
Investor1337
Posted - 6 days ago
$GLTO All time low adding
bionk13
Posted - 1 week ago
$GLTO Every day that goes by, I get more convinced that the company focuses all its resources on the ongoing GB1211+Keytruda trial. It’s make it (big) or break it and we will have to wait without updates until spring 2025.
Investor1337
Posted - 1 week ago
$GLTO Hans working from home? leases ended nov?
arribaStocktrading
Posted - 1 week ago
$GLTO The cash burn was less than expected and people cheer this, but it would also seem to suggest that business operations have completely stalled. Somebody needs to point out that every silver lining has a cloud attached to it. I would love to see this stock go up. If anything I'm looking for a reason to buy more but not coming up with anything yet.
flowerchefstocks
Posted - 1 week ago
@Mitchee01 Really good article think it might have helped people see the true potential of the science. Anyone see the market cap of $BIXT or $GLTO - Super cheap. Both under $10 million. Gotta listen to this video. I think these other galectin companies could represent big upside if $GALT readout is good and we all know its almost a given. https://www.youtube.com/watch?v=YGeoim7A_jM
flowerchefstocks
Posted - 1 week ago
$GALT Disrupting Merck - great article that speaks to the power of galectin blockers and how important it is for Keytruda to even work. See this article conclusively proves that Galectin-3 occupies the receptor binding location of PD-1 and thats bad for the PD-1 blockers. Great detail in this article. $BIXT $GLTO mentions https://www.insiderfinancial.com/post/galectin-therapeutics-nasdaq-galt-disrupting-mercks-cancer-dominance
leecoq
Posted - 2 weeks ago
$GLTO ???? The Company has no finance leases
Investor1337
Posted - 2 weeks ago
$GLTO
PalladiumMidas19
Posted - 2 weeks ago
$GLTO Wow they beat.
joe77w
Posted - 2 weeks ago
$GLTO 21 mln in net equity / 1.5 mln shares fully diluted does mean 14 usd
joe77w
Posted - 2 weeks ago
$GLTO I Wont sell , this co has cash and net equity over 13 USD, every positive news about trials and partnership May send It to the Moon, my opinion
skyrockets_Inc
Posted - 2 weeks ago
$GLTO More cash left than I thought ~19M,
Investor1337
Posted - 10/31/24
$GLTO Regardless of the checkpoint inhibitor the galectin antagonist is relevant to all cancer treatments including chemo and radiation.
Investor1337
Posted - 10/31/24
$GLTO Historically Tecentriq has a 22- 38% objective response rate (ORR) but at the highest dose GB1211 had at 60% response rate which is close to double assuming the average response rate.
skyrockets_Inc
Posted - 10/31/24
$GLTO I put a lot of my money in $CYCN for now. Similar situation GLTO was in, waiting on news for an in-license/merger hopefully. But as we know with all of these things, who knows on the timing. I'm hoping that news comes soon (it's been over a year now) and then I'll probably re-buy some GLTO at these prices. If you're feelin' froggy come join for a potential CYCN move. Some compelling things about CYCN are the 30% ownership by it's former CEO Peter Hecht. And they own 10% equity in the private company Tisento Therapeutics. Lot's of other compelling traits, including large institutional ownership and low float. If interested for more details message me.
flowerchefstocks
Posted - 10/31/24
$BIXT Going to listen to this in 30 min Looks like hes going to be talking about Galectins and cancer. Had me at Galectins https://x.com/MikeSheikh2/status/1851658320710664211 $GALT $GLTO $GLYC
sixmilliondollarman
Posted - 10/30/24
$GLTO 👇interesting posts below👇
I’ve made a case for Bausch Health but the case for Merck has been obvious. When considering Keytruda sales it made sense for them not to screen for Galectin-3. However I believe now it’s in their best interest. The data is catching up and can no longer be ignored. Even more importantly Keytrudas strongest patents expire in 2028. Even with a new formulation, injection vs IV, maybe they keep a quarter of their sales. Injection isn’t going to improve efficacy so there’s going to be a payer issue regarding bio similars even with a new patent for formulation. Payers would rather pay for cheaper bio similar IV vs new Keytruda injection. Further more IV is every 3 -6 weeks so the convenience of injection vs IV is not going to be a very strong argument imo. But a combo treatment with selvigaltin significantly improves efficacy. A combination patent is the way to go for Merck imo 🤷‍♂️
arribaStocktrading
Posted - 10/30/24
$GLTO Reality check. The studies needed to make Galectin-3 inhibitors into a household name are going to take a tremendous amount of cash and resources that this company obviously does not have and what is the holdup on getting a partnership deal done? Apparently, we've learned too that Merck has been actively behind the scenes discouraging testing for Gal-3 expression in patients because it would mean not selling Keytruda to a large swath of the patient population that would not respond to it according to the results of a Gal-3 expression test. We know that Big Pharma wields its weight around and can affect the landscape in ways that benefit them over the health of the patients. So it's not enough to just have a better treatment option to offer. Yes, we believe in the Science but you can go broke believing in the Science too - Unfortunately. Every quarter that goes by and the company is just burning cash puts it in a worse position to deliver for the Shareholders.
tradingtwenty
Posted - 10/30/24
Top 5 stocks by smallest market cap that have trended in the past 24 hours: $BKYI 3.74M🔥 $SHPH 5.3M $PRTG 6.24M $UPXI 8.9M $GLTO 9.28M Link: https://tradingtwenty.com/dashboard/trending/past
flowerchefstocks
Posted - 10/30/24
$MRK This is BIG News - They found out why Keytruda doesn't work in 60% of the people they are treating. The good news they can make Keytruda 100% effective - the bad news its going to cost 60% of existing patients. Bigger news is that if the combine drug with a #galectin antagonist they get back the 60% they lost. https://www.linkedin.com/pulse/keytruda-neutralized-galectin-3-over-60-patients-michael-sheikh-mcowc/ $BIXT $GLTO $GALT
flowerchefstocks
Posted - 10/30/24
$GALT This video was posted 3 weeks ago talks all about cancer & #galectins mentions GALT and $GLTO study results in #cancer. This is the highlight reel - if you scroll down there is a link to the full interview. Very enlightening and worth the 3 min. https://www.youtube.com/watch?v=NNAqPXoJIRk